JPRN-UMIN000007413
Completed
Phase 2
Phase II Study of Safety and Efficacy. Dasatinib in Patients with Chronic Phase Chronic Myelogenous Leukemia achieving a Major Molecular Response on Imatinib. - Dasatinib CMR-trial
CML stem cell study group0 sites20 target enrollmentMarch 1, 2012
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Chronic phase chronic myelogenous leukemia
- Sponsor
- CML stem cell study group
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Active double cancer 2\)Pregnant or breastfeeding woman 3\)Patient who has clear pleural effusion 4\)Patient who have the anamnesis or complications of a cardiovascular disorder with serious or poor control. \-myocardial infarction within 6 months \-angina pectoris within 3 months \-congestive heart failure within 3 months \-congenital long QT syndrome
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A clinical trial to test the safety, efficacy and plasma concentration of G1T28 in patients with metastatic triple negative breast cancer receiving gemcitabine and carboplatin chemotherapyocally recurrent or metastatic Triple Negative Breast CancerMedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-004466-26-BGG1 Therapeutics90
Active, not recruiting
Phase 1
A clinical trial to test the safety, efficacy and plasma concentration of G1T28 in patients with metastatic triple negative breast cancer receiving gemcitabine and carboplatin chemotherapyEUCTR2016-004466-26-SIG1 Therapeutics90
Active, not recruiting
Phase 1
A clinical trial to test the safety, efficacy and plasma concentration of G1T28 in patients with metastatic triple negative breast cancer receiving gemcitabine and carboplatin chemotherapyocally recurrent or metastatic Triple Negative Breast CancerMedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-004466-26-BEG1 Therapeutics90
Active, not recruiting
Phase 1
A clinical trial to test the safety, efficacy and plasma concentration of G1T28 in patients with metastatic triple negative breast cancer receiving gemcitabine and carboplatin chemotherapyEUCTR2016-004466-26-HRG1 Therapeutics142
Active, not recruiting
Not Applicable
Evaluation of efficacy and safety of analgesia with transmucosal fentanyl citrate in oncologic patients eligible to permanent central venous catheterEUCTR2012-002469-37-ITCENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO